News

Published on 24 Mar 2024 on Insider Monkey via Yahoo Finance

20 Best Websites and Blogs For ETF Research


Article preview image

In this article, we discuss 20 best websites and blogs for ETF research. If you want to skip our discussion on the ETF industry, head over to 5 Best Websites and Blogs For ETF Research. 

Since the launch of the first United States ETF in 1993, these financial instruments have evolved significantly. Several trends are expected to fuel the continued growth of ETFs, potentially propelling global ETF assets to $14 trillion by the end of 2024. Investors are now displaying strong bullish sentiment towards bonds, marking the highest level of optimism since the Global Financial Crisis, according to a recent Bank of America survey. The survey reveals a significant shift as investors favor bonds over cash, resulting in the largest overweight positions in bonds since 2009. Notably, bond ETFs have attracted 43% of all ETF flows, surpassing their 20% share of total ETF assets. 

Similarly, in 2023, active ETFs experienced significant growth, particularly in the United States, where they attracted substantial flows despite having relatively smaller assets under management (AUM). This surge in interest is evident with new active ETF launches and mutual fund-to-ETF conversions over the past year. A PwC survey of ETF leaders indicates a strong expectation of continued demand for active ETFs in the coming years. About 76% of respondents anticipate "significant" active ETF demand in the next two to three years, positioning the U.S. as the second-highest region globally, with 82% of Canadian leaders expecting significant demand. Another PwC survey indicates optimistic expectations for the growth of global ETF assets under management. Approximately 70% of respondents anticipate that the ETF AUM will reach $15 trillion or more by June 30, 2027. Furthermore, nearly one-third of respondents (29%) hold a more bullish outlook, projecting that ETF AUM will more than double to at least $18 trillion by the same date. These projections indicate a compound annual growth rate of 11.77% and 15.92%, respectively.

NYSE.LLY price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
14 Dividend Growth Stocks with Highest Growth Rates

In this article, we discuss 14 dividend growth stocks with highest growth rates. You can skip our...

Insider Monkey via Yahoo Finance 24 Apr 2024

Eli Lilly and Company (LLY) Rose due to Robust Q4 Sales

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarte...

Insider Monkey via Yahoo Finance 23 Apr 2024

Wisconsin pharmaceutical plant sold to pharma leader Eli Lilly Wisconsin family owned pharma plant...

Eli Lilly and Company, the pharmaceutical giant, has finalized the acquisition of a production...

WISN 12 Milwaukee 22 Apr 2024

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Eli Lilly and Company LLY announced that its pipeline candidate, tirzepatide, met all primary and...

Zacks via Yahoo Finance 18 Apr 2024

Company News for Apr 18, 2024

Eli Lilly and Company (LLY) shares rose 0.5% after announcing positive late-stage results for its...

Zacks via Yahoo Finance 18 Apr 2024

14 Best Large Cap Dividend Growth Stocks To Buy Now

In this article, we discuss 14 best large-cap dividend growth stocks to buy now. You can skip our...

Insider Monkey via Yahoo Finance 18 Apr 2024

Eli Lilly's Mounjaro, Zepbound to remain in shortage through end of Q2 (NYSE:LLY)

Eli Lilly's semaglutide-based drugs for diabetes and weight loss, Mounjaro and Zepbound, will fac...

Seeking Alpha 17 Apr 2024

Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says

Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea,...

CNN.com 17 Apr 2024

The Week in Pictures: April 5 - April 12

From the ongoing conflict between Israel and Hamas, to UEFA Champions League quarter finals, to t...

dpa international via Yahoo News 12 Apr 2024

GLP-1s benefit Parkinson’s: Barclays sees biopharma impact

Barclays cites implications for the biopharma sector after a mid-stage trial showed that the GLP-...

Seeking Alpha 12 Apr 2024